Recent advances in managing overactive bladder

F1000Res. 2020 Sep 11:9:F1000 Faculty Rev-1125. doi: 10.12688/f1000research.26607.1. eCollection 2020.

Abstract

Overactive bladder syndrome (OAB) is defined as urinary urgency, usually accompanied by frequency and nocturia, with or without urgency incontinence, in the absence of urinary tract infection or other obvious pathology. In this review, we focus on recent advances in the management of OAB. We examine the evidence on the effect of anticholinergic load on OAB patients. Advances in medical treatment include a new beta-3 agonist, vibegron, which is thought to have fewer drug interactions than mirabegron. Treatment of genitourinary syndrome of the menopause with oestrogens and ospemifene have also shown promise for OAB. Botulinum toxin has been shown to be an effective treatment option. We discuss the new implantable neuromodulators that are on the market as well as selective bladder denervation and laser technology.

Keywords: Advances; OAB; overactive bladder; treatment.

Publication types

  • Review

MeSH terms

  • Acetanilides / therapeutic use
  • Adrenergic beta-3 Receptor Agonists / therapeutic use
  • Botulinum Toxins / therapeutic use*
  • Denervation*
  • Drug Implants / therapeutic use*
  • Humans
  • Laser Therapy*
  • Pyrimidinones / therapeutic use*
  • Pyrrolidines / therapeutic use*
  • Tamoxifen / analogs & derivatives
  • Tamoxifen / therapeutic use
  • Thiazoles / therapeutic use
  • Treatment Outcome
  • Urinary Bladder, Overactive / therapy*

Substances

  • Acetanilides
  • Adrenergic beta-3 Receptor Agonists
  • Drug Implants
  • N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide
  • Pyrimidinones
  • Pyrrolidines
  • Thiazoles
  • Tamoxifen
  • Ospemifene
  • Botulinum Toxins
  • mirabegron

Grants and funding

The author(s) declared that no grants were involved in supporting this work.